According to Aridis Pharmaceuticals, the Cystic Fibrosis Foundation has made a $4.85 million investment in Aridis common stock to support continued development of AR-501 nebulized gallium citrate for the treatment of chronic lung infections in CF patients, bringing the CF Foundation’s total funding for the project to $12.5 million.
AR-501 has been granted orphan, Fast Track, and Qualified Infectious Disease Product (QIDP) designations in the US and received orphan drug designation from the EMA in 2019. Aridis says that a Phase 2a study of AR-501 in CF patients recently completed enrollment, and topline results are expected in the first quarter of 2023.
Aridis Pharmaceuticals CEO Vu Truong commented, “We want to thank the CF Foundation for their continued support for the clinical development of AR-501, an inhaled form of gallium, which we believe could be a more effective delivery route than intravenous (IV) administered gallium. IV gallium has already demonstrated that it is well tolerated and improved lung function in a CF Foundation, National Institutes of Health, and FDA funded Phase 2 clinical study.”
Read the Aridis Pharmaceuticals press release.
